AusBiotech 2018 Program


 Click the above button to view the program

 Key topics

  • Regenerative medicine and its potential to provide solutions for previously untreatable conditions and diseases
  • Clinical trials, including strategies to help Australia maintain its competitive advantage and continue to attract international R&D
  • Drugs, vaccines, diagnostics and controls for tropical diseases
  • Key issues facing the global big pharma industry
  • Gene editing technologies
  • Fostering Australian innovation, with an update on the Innovation System Review
  • Big data and precision medicine
  • Australia's formulation development capabilities with regards to pre-clinical testing
  • Life science commercialisation and innovation
  • Managing R&D processes
  • Complementary medicines, examining academic collaborations and research outcomes
  • Agriculture and agbiotech
  • Intellectual property

The annual AusBiotech conference brings together Australian and international biotech leaders and stakeholders. For more than three decades, the event has created a forum to reflect on the sector’s achievements and exchange ideas to further advance the sector’s standing both nationally and globally.

AusBiotech is dedicated to consolidating this growth, and our 2018 conference will once again present issues critical to industry. Global biotech trends, breakthroughs, challenges and success stories will feature prominently on the program. Panel discussions and key themes will cover regulation and reimbursement, research translational strategies, new markets, business development and capital access, emerging technologies, clinical trials and commercialisation. 


Millis Orator - proudly supported by CSL

The Millis Oration is named after Emertius Professor Nancy Millis (1922-2012), the First Lady of biotechnology.

Past speakers:

Dr Carol Dahl, Chief of Staff, Global Health Program & Director, Global Health Technologies, Bill & Melinda Gates Foundation, USA

Dr Alan Trounson, President, California Institute for Regenerative Medicine, California USA

Dr Megan Clark, Chief Executive, CSIRO, Australia

Professor Nadia Rosenthal, Director, Australian Regenerative Medicine Institute, Monash University, Australia

Professor Ross McKinnon, Research Director and Professor in Cancer Research, Flinders Centre for Innovation in Cancer, School of Medicine, Flinders University, Australia

Dr Alan Robertson, Chief Executive Officer, Pharmaxis, Australia

Dr Mark Shackleton Medical Oncologist & Group Leader, Melanoma Research Laboratory Peter MacCallum Cancer Centre, Australia
Professor Goran Roos Chair, Advanced Manufacturing Council, Australia
Professor Balram Bhargava Professor of Cardiology, All India Institute of Medical Sciences

Prof Frank Gannon Director & CEO, QIMR Berghofer Medical Research Institute, Australia

Professor Carola Vinuesa, Head, Department of Pathogens and Immunity, Australian National University College of Medicine, Biology and Environment

Prof Ian Gust, Professorial Fellow, University of Melbourne, Australia

Dr Glenn Begley, CEO, BioCurate Pty Ltd, Australia

Professor Doug Hilton, Institute Director, Division Head of molecular Medicine, Walter & Eliza Hall Institute, Australia


Early Stage Investment Event

One day investment event bringing world-leading biotech innovators together with Australia's early stage investment community to fund the future of life sciences.  Featuring a mix of expert keynotes and life sciences company presentations, the event merges market intelligence with investment opportunities and will encourage successful biotech investment.


Other features

  • BioIndustry Exhibition Hall
  • Satellite events
  • AusPartnering, AusBiotech’s highly recommended business matching program
  • Trade day


We gratefully acknowledge our session partners: